Insulin-2-derived peptide-MHC complex (Ins-MHC)

The Insulin-2-derived peptide-MHC complex is a primary autoantigenic target in the development of Type 1 Diabetes (T1D), particularly studied in the Non-Obese Diabetic (NOD) mouse model (Nakayama et al., Nature, 2005). In these models, peptides derived from the B-chain of Insulin-2, most notably the B:9-23 sequence, are presented by MHC class II molecules (such as I-Ag7 in mice or HLA-DQ8 in humans) to autoreactive CD4+ T cells (Unanue, Adv Immunol, 2014). This recognition event is a critical checkpoint in the loss of immune tolerance, leading to the T cell-mediated destruction of pancreatic beta cells (Michels et al., Diabetes, 2011). Therapeutic interventions targeting this complex seek to reprogram the immune system by inducing regulatory T cells or promoting anergy in pathogenic T cells (Alleva et al., J Immunol, 2002). Current research focuses on antigen-specific immunotherapies, including altered peptide ligands like NBI-6024 and nanoparticle-based delivery systems, to prevent or reverse the progression of T1D without systemic immunosuppression (Gottlieb et al., Diabetes Care, 2009). Understanding the structural basis of how these peptides bind to MHC is essential for developing precision immunotherapies for T1D.

Other names

Insulin B:9-23 peptide-MHC complexInsulin-2 B-chain peptideInsulin autoantigenpMHC complexInsulin-2 B:9-23 epitope

Antigen-specific immunotherapy designed to induce immune tolerance by presenting autoantigenic peptides in a non-inflammatory context, thereby promoting the generation of regulatory T cells (Tregs) or inducing anergy in pathogenic CD4+ T cells.